We report herein the first gene fusions discovered
in ovarian cancer. We conclude that gene fusions are not infrequent events in ovarian cancer and that these events have the potential to substantially alter the expression patterns of the genes involved; gene fusions should therefore be considered in efforts to comprehensively characterize the mutational profiles of ovarian cancer transcriptomes.”
To investigate 5 years’ experience with fine needle aspiration (FNA) of salivary glands at a single academic center.
A total of 191 salivary gland FNAs were performed at Louisiana State University Health Science Center from 2003 to 2007, and all were done on major salivary glands except for 1 case.
The cytologic diagnoses included 17 malignancies, 6 atypia, 73 neoplasms, 87 negative selleck chemicals llc and IS nondiagnostic. Eighty-six cases had histologic follow-up (45.0%). There were 5 false negatives: 2 adenoid cystic carcinomas, I acinic cell carcinoma, I polymorphous low grade adenocarcinoma and I metastatic basaloid squamous cell carcinoma. The only false positive was a pleomorphic adenoma misdiagnosed as adenoid cystic carcinoma. Four reactive processes were diagnosed
as benign neoplams, including 2 granulomatous inflammation and 2 chronic sialadenitis. Five benign neoplasms were interpreted as reactive processes, including 2 Warthin’s tumors, 2 sebaceous find more lymphoadenomas and I pleomorphic adenoma. The overall accuracy in distinguishing benign from malignant
lesions was 79.1%, and the sensitivity for salivary neoplasia was 89.4%.
Our results are consistent with the literature that salivary gland FNA has good sensitivity, specificity and accuracy in the AZD4547 manufacturer diagnosis of salivary neoplasms. FNA can play a significant role in triaging patients with onsite cytologic interpretation and can reduce many unnecessary surgeries. (Acta Cytol 2009,53:375382)”
“Background: Recent studies have demonstrated that systemic or topical PUVA therapy, i.e., ultraviolet A (UVA) irradiation following treatment with 8-methoxypsoralen (8-MOP), is effective against the sclerotic skin lesions in systemic sclerosis. However, the mechanisms still remain unknown.
Objective: To clarify the mechanisms of this therapy, we created a mouse model of bleomycin (BLM) injection-induced scleroderma and evaluated the effects of PUVA on the fibrotic lesions of scleroderma in this mouse model.
Methods: BLM was injected subcutaneously once a day into the mice for 24 days. During the injection period, one group of mice was irradiated with UVA following local application of 8-MOP. Control groups were also set up, which were injected with phosphate-buffered saline, instead of BLM.